Frontiers in immunology

Gene-silencing therapy for gastrointestinal and genitourinary tumors

Updated

Abstract

Essence

This review summarizes how oligonucleotide therapies may expand cancer treatment by silencing hard-to-drug targets in gastrointestinal and genitourinary tumors.

Evidence

Review of , , and , covering their structures, mechanisms, delivery strategies such as lipid nanoparticles and GalNAc conjugates, and reported clinical applications in gastrointestinal and genitourinary cancers.

Caveat

The evidence is largely a synthesis of prior work, and the abstract highlights persistent barriers to clinical use including degradation, poor cellular uptake, and off-target effects.

Simplified

Key numbers

43%
FDA-approved targeted therapies
Percentage of targeted precision therapies among 198 FDA-approved drugs from 1998 to 2022.
2018
Nusinersen approval
Year nusinersen was approved for spinal muscular atrophy treatment.
38%
38% pathological complete response
Pathological complete response rate in a neoadjuvant study of apatorsen for non-muscle invasive bladder cancer.

Key figures

Figure 1
Mechanisms of regulating gene expression via RNA cleavage or blockade
Highlights distinct ASO strategies controlling gene expression by degrading or blocking to modulate protein production
fimmu-16-1657040-g001
  • Panel A
    RNase H-dependent cleavage where ASOs bind mRNA forming DNA-RNA duplexes that cleaves, causing mRNA degradation
  • Panel B
    where or guide to target mRNA, leading to mRNA cleavage or translational repression
  • Panel C
    where ASOs bind mRNA regions blocking the 40S ribosomal subunit, preventing translation without degrading mRNA
  • Panel D
    modulation where ASOs target splice sites or regulatory motifs, altering or inclusion to modify protein isoforms
Figure 2
The process of therapy silencing gene expression inside cells
Highlights how siRNA therapy targets and reduces specific to silence gene expression inside cells
fimmu-16-1657040-g002
  • Panel single
    Encapsulated double-stranded siRNA enters the cell and is incorporated into the RNA-induced silencing complex ()
  • Panel single
    siRNA duplex is unwound into passenger and guide strands by helicase using ATP energy
  • Panel single
    Passenger strand is degraded while guide strand binds (Ago2) protein within RISC
  • Panel single
    Guide strand directs RISC to complementary targeted mRNA, leading to its cleavage and degradation
1 / 2

Full Text

What this is

  • This review discusses gene expression silencing therapies, focusing on gastrointestinal and genitourinary tumors.
  • It covers (), (), and (), detailing their mechanisms and clinical applications.
  • The review highlights recent advancements that enhance the efficacy and reduce the toxicity of these therapies.

Essence

  • Gene expression silencing therapies, including , , and , offer targeted treatment options for cancers that are resistant to conventional therapies. Recent advancements in chemical modifications and delivery systems have improved their clinical applicability.

Key takeaways

  • Gene expression silencing therapies can target previously "undruggable" genes, providing new avenues for cancer treatment. , , and each have unique mechanisms that allow for precise modulation of gene expression.
  • Chemical modifications, such as phosphorothioate linkages and sugar modifications, enhance the stability and efficacy of oligonucleotide therapies. These advancements help overcome challenges like degradation and poor cellular uptake.
  • Clinical trials have shown promising results for and in treating various cancers, including prostate and bladder cancer. However, challenges remain, including off-target effects and the need for effective delivery systems.

Caveats

  • Despite advancements, gene expression silencing therapies face significant challenges, including tumor heterogeneity and the emergence of resistance mechanisms. These factors can limit their overall effectiveness in clinical settings.
  • Off-target effects and immune activation remain concerns with oligonucleotide therapies, necessitating careful design and optimization to minimize risks.

Definitions

  • Antisense oligonucleotides (ASOs): Short, single-stranded DNA or RNA molecules designed to bind to specific mRNA sequences, modulating gene expression.
  • Small interfering RNAs (siRNAs): Double-stranded RNA molecules that mediate RNA interference, leading to the degradation of target mRNA and silencing gene expression.
  • MicroRNAs (miRNAs): Small non-coding RNAs that regulate gene expression post-transcriptionally, often affecting multiple target mRNAs simultaneously.

Simplified

Funding

Competing interests

No commercial or financial ties reported.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free